BioCentury
ARTICLE | Distillery Therapeutics

Dermatology

May 16, 2017 2:12 PM UTC

Mouse studies suggest inhibiting SYK could help treat neutrophilic dermatosis. In a mouse model of the disease, myeloid-specific knockout of SYK delayed disease onset and lesion severity in the footpad compared with normal SYK expression. Next steps could include testing SYK inhibitors in models of neutrophilic dermatosis.

Rigel Pharmaceuticals Inc. has Tavalisse fostamatinib, an oral SYK inhibitor, in registration to treat idiopathic thrombocytopenic purpura (ITP) and Phase II testing to treat chronic autoimmune hemolytic anemia and IgA nephropathy...